Fig. 1.
Event-free survival and survival distributions for patients with recurrent malignant astrocytomas treated with either conventional chemotherapy (Chemo, n=56) or myeloablative chemotherapy with autologous bone marrow rescue (ABMR, n=27). Chemo versus ABMR unstratified comparison of event-free survival: p=0.014 [hazard ratio=1.9 (95% confidence interval 1.1–3.2)]. Chemo versus ABMR unstratified comparison of survival: p=0.018 [hazard ratio=1.9 (95% confidence interval 1.1–3.1)]